Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor Efficacy
M. G. Lechner, A. Y. Patel, W. Hugo, T. E. Angell, M. I. Cheng, M. S. Pioso, A. T. Hoang, N. Yakobian, E. C. McCarthy, H.-C. Chen, E. D. Rodriguez, L. Guo, M. Astourian, A. Drakaki, P. Famini, , M. A. Su
This study shows that inhibiting the IL-17A axis reduces immune-related adverse events in checkpoint inhibitor-treated mice without affecting anti-tumor efficacy.
bioRxiv · Jan 19, 2022Immunology